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Abstract
The human p73 gene is a homolog of p53, which has
been localized to chromosome 1p36 in a region that is
frequently deleted in neuroblastoma. Transfection of the
p73 gene into neuroblastoma cells that lack detectable
p73 protein has been shown to result in growth
suppression and to induce neuronal differentiation. In
this study, we have identified by means of restriction
landmark genome scanning (RLGS) a genomic frag-
ment that was frequently reduced in intensity in neuro-
blastomas. The cloned fragment contained exon 1 of
p73 as well as intronic and promoter sequences. We
investigated the genomic and expression status of p73
and N-myc in 34 neuroblastoma tumors and 12 neuro-
blastoma cell lines. Approximately a third of neuro-
blastomas in our series exhibited deletion of p73. Most
tumors analyzed exhibited reduced expression of p73,
as determined by quantitative RT-PCR, in the absence
of detectable p73 gene deletion. The reduced expres-
sion of p73 correlated with overexpression of N-myc in
a statistically significant manner. The N-myc gene was
transfected into two neuroblastoma cell lines that
lacked N-myc amplification to determine its effect on
p73 RNA levels. p73 was detectable at low level by RT-
PCR in untransfected SK-N-AS cells and became
undetectable following N-myc transfection, whereas in
SH-EP1 cells, p73 levels were substantially reduced
following transfection but remained detectable. Our
data suggest that the N-myc gene modulates expres-
sion of p73, allowing neuroblastoma cells to escape the
growth suppressing properties of p73.
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Introduction
The p73 gene encodes a protein with significant amino acid
sequence homology and functional similarity with p53 [1 ].
Overexpression of p73 activates the transcription of p53
target genes and inhibits cell growth by inducing apoptosis
[2 ]. p73 maps to chromosome 1p36, in a region frequently
deleted in neuroblastomas and other human cancers [3–6]
raising the possibility that in neuroblastoma, inactivation of
p73 may contribute to tumorigenesis.
Neuroblastoma is a tumor of neural -crest–derived cells of
variable severity. Amplification of the N-myc oncogene
occurs in approximately one- third of neuroblastomas and
correlates with aggressive disease [7]. There is conclusive
evidence that targeted expression of N-myc in transgenic
mice results in neuroblastomas that exhibit features of human
neuroblastomas [8]. The identity of genes that play a role in
neuroblastoma development in the absence of N-myc
amplification is largely unknown. There is evidence that the
1p36 region may contain at least two tumor-suppressor
genes [9,10]. Neuroblastoma tumors lacking N-myc ampli-
fication frequently contain relatively small 1p36 deletions,
suggesting that this region, which encompasses p73,
contains a tumor suppressor. Tumors with N-myc amplifica-
tion contain larger deletions that extend proximally beyond
the location of p73, suggesting that the extended region
contains another tumor-suppressor gene. Whereas expres-
sion analysis supports a potential role for p73 in neuro-
blastoma [11], conclusive functional evidence that links p73
inactivation to the development of neuroblastoma is currently
lacking. p73 -deficient mice have neurological defects but
lack spontaneous tumors [12]. There is also lack of genetic
evidence that points to inactivation of p73 by point mutations
[5,6,13]. Thus, the identity of tumor-suppressor gene(s) that
play a role in neuroblastoma tumor initiation or progression
and that may reside in the 1p36 region remains to be
determined. Nevertheless, given the evidence that p73
activates the transcription of p53 target genes and inhibits
neuroblastoma cell growth and induces neuronal differ-
entiation [1,14], analysis of the expression patterns of p73
in neuroblastoma may be relevant to our understanding of
abnormal proliferation in this malignancy.
We have utilized restriction landmark genome scanning
(RLGS) to detect novel genomic alterations in neuroblas-
toma cell lines and primary tumors [15,16]. The RLGS
approach to scan the whole genome allows the identification
and isolation of as yet unknown amplified, deleted or
methylated sequences. The use of the enzyme Not I to digest
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DNA and the tagging of the fragments at the Not I ends
allows preferential visualization and quantitative analysis of
fragments containing CpG islands. Using this approach, we
have cloned a novel gene referred to as NAG, that is
frequently co-amplified with N-myc in neuroblastoma [17].
We have developed informatics tools for comparisons of
sample derived RLGS patterns with patterns predicted from
the human genome sequence and displayed as virtual
genome scans (VGS) [18]. The tools developed allow
sequence prediction of fragments in RLGS patterns obtained
with different restriction enzyme combinations. The utility of
VGS has been demonstrated by the identification of
restriction fragment length polymorphisms, and of amplifica-
tions, deletions, and methylation changes in tumor-derived
CpG islands [19]. We have also developed a strategy for the
analysis of RLGS patterns of neuroblastomas and control
tissues for the detection of chromosome 1 fragments that are
either absent or that exhibit diminished intensity in tumor
patterns [20]. In this study, one such genomic fragment was
identified as encompassing exon 1 of the p73 gene, leading
us to determine the relationship between N-myc amplifica-
tion and overexpression on the one hand and p73 deletion
and reduced expression on the other. We provide evidence
that N-myc plays a role in regulating expression of p73. N-
myc amplified tumors exhibited reduced expression of p73,
independent of p73 gene deletion. In addition, transfection of
neuroblastoma cell lines with N-myc resulted in reduced
expression of p73.
Materials and Methods
Two-Dimensional Gel Electrophoresis
High-molecular -weight DNA was extracted from 34
neuroblastoma tumor specimens obtained at the time of
diagnosis and 12 neuroblastoma cell lines. DNA was
subjected to RLGS analysis, as previously described [16].
Briefly, 3 g of DNA was used for digestion with Not I and
EcoRV. The Not I -derived 5’ protruding ends were labeled
with 32P-marked nucleotides (EcoRV yields blunt ends).
The labeled fragments were directly applied onto first -
dimension agarose gels before electrophoresis. Separated
fragments were treated in situ with Hin fI for further cleavage,
before second-dimension separation in acrylamide slab
gels. The gels were subsequently dried and exposed to
PhosorImager plates (Molecular Dynamics, Piscataway,
NJ). Images were obtained after scanning of the Phosphor-
Imager plates. Analysis of p73 spot intensity was undertaken
by an investigator that was blinded to the N-myc and p73
expression status of the samples from which the RLGS were
derived. The intensity of the p73 fragment in RLGS was
estimated relative to the intensity of invariant neighboring
fragments.
Southern Blot Analysis
Genomic DNA was digested with Not I and EcoRV before
electrophoresis and blotting. Filters were hybridized with a
1.4-kb random- labeled NotI–Hind III p73 genomic fragment
derived from a 1.7-kb Not I–EcoRV fragment cloned from
preparative RLGS patterns. The same filters were also
hybridized with a 1.4-kb Not I–DpnII unrelated chromosome
1–derived genomic fragment that contains part of the GAC1
gene [21]. N-myc amplification was also determined by
Southern blotting using an N-myc cDNA as probe.
Construction of a Chromosome 1 NotI– EcoRV Fragment
Library
Metaphase chromosomes were isolated from the human
lymphoblastoid cell line GM-1130B obtained from the
American type Culture Collection (Rockville, MD), using
the polyamine isolation buffer described previously [22].
Isolated chromosomes were stained with two fluorochromes,
Hoechst 33258 and chromomycin A3 (Calbiochem, La Jolla,
CA), and allowed to stand for 48 hours using a combination
of slow centrifugation and sedimentation. Two million
chromosomes 1 were sorted into siliconized glass tubes.
Chromosome 1 genomic DNA was digested first with Not I
and ligated to the Not I and EcoRV digested plasmid vector
Bluescript SK+ (Strategene, La Jolla, CA) with T4 ligase
(Roche Molecular Biochemicals, Indianapolis, IN). After the
first ligation and phenol /chloroform extraction, the DNA was
digested with EcoRV and purified with phenol /chloroform
extraction–ethanol precipitation. The EcoRV ends were
ligated. The circular DNA was introduced into Epicurian coli,
XL1-blue MRF0 cells by electroporation according to the
conditions recommended by the manufacturer. Genomic
library DNA was subjected to RLGS analysis as described
above.
Cloning of a Not 1 Containing p73 Genomic DNA Fragment
For cloning of fragment Ch1-113, 1.1 g of the library
DNA was digested with Not I and EcoRV. An aliquot of
digested DNA was labeled at the Not I ends with [32P]dCTP
and dGTP. The labeled DNA was mixed with unlabeled
library DNA and subjected to electrophoresis. DNA labeling
allowed detection of the fragment in RLGS pattern.
Unlabeled DNA served to increase the yield for cloning of
fragments extracted from gels. The separated fragments
were treated with Hin fI for further cleavage, in situ. The
Hin fI -digested DNA fragments were separated in the
second dimension as for tumor DNA, and the resulting gel
was exposed against X-ray film for 3 days at 808C. A
fragment in the position of Ch1-113 was extracted from the
gel and ligated into modified Bluescript SK-vector sets,
followed by electroporation into Epicurian coli, XL1-blue
MRF0 cells and transformed bacteria colony selection. The
correspondingNot I–EcoRV fragment was obtained by using
the 32P- labeled Not I–Hin fI fragment as probe for screening
the chromosome 1 library.
RNA Samples and RT-PCR
Total RNA was extracted from neuroblastoma tumors and
cell lines using Trizol reagent (Life Technologies, Rockville,
MD). Two micrograms of each total RNA was reverse
transcripted into single-stranded DNA with Superscript II
reverse transcriptase (Life Technologies) and random
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primers according to the conditions recommended by the
manufacturer. One microliter of the products was amplified
with Expand High Fidelity PCR System (Roche Molecular
Biochemicals) in 25 l of reaction that contained 1.75 U of
polymerase, 20 pM of each primer, 1 buffer (with 1.5 mM
MgSO4), 12.5 nM of each dNTP, and 5% DMSO. The
amplification process was as previously described [23] and
consisted of 30 cycles of 608C/0.5 minute, 718C 2 minutes,
and 938C/0.5 minute after starting with a denaturation step
at 938C for 3 minutes and ended at 728C for 10 minutes.
PCR was undertaken using double primers as follows.
Primers were designed to achieve the same parameters for
primer Tm, GC content and length. The size of the targeted
regions was chosen to achieve a comparable size while
allowing resolution of the PCR products by agarose gel
electrophoresis.
p73 primers: forward primer 50GAACCAGACAGCACCT-
AGCACCTACTTCG; reverse primer: 50 GACAGGGTCATC-
CACATACTGC.
N-myc primers: forward primer 50 TCCACCAGCAGCA-
CAACTATG; reverse primer: 50 GTCTAGCAAGTCCGAGC-
GTGT.
Alternatively one set of double primers consisted of
ubiquitin primers relied upon as a control: forward primer:
50 TGACACAATCGAGAACGTCAAG; reverse primer: 50 AT-
GCCTTCCTTGTCTTGGATCT.
All PCR reactions were undertaken at least twice to
ensure consistency.
N-myc Transfection
Neuroblastoma cell lines were maintained in MEM
supplemented with 10% fetal bovine serum, 2mM glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin. SH-EP1
and SK-N-AS cells were stably transfected with the
pCMVmyc expression plasmid or native pSMneo vector
(gifts of William Fahl, McArdle Laboratory for Cancer
Research, Madison, WI) using Lipofectamine (Life Tech-
nologies) as described by the manufacturer. Cells (5104)
were plated on 35-mm dishes in serum-free media and
transfected with 10 g of plasmid DNA (pCMVmyc or
pSMneo ). Twenty- four hours following transfection, 20%
MEM was added to the plates. At 48 hours, cells were
trypsinized and transferred to 100-mm dishes and the media
was supplemented with G418. Individual G418 colonies
were transferred using filter paper soaked in trypsin and
subcultured in six-well dishes. N-myc expression was
determined by Western blotting. Following stable trans-
fection, cells were cultured in 10% MEM containing G418
(Geneticin; Gibco, Carlsbad, CA) at 500 g/ml.
Results
A Notl Fragment with Diminished Intensity in Neuroblastoma
RLGS Patterns Contains a p73 CpG Island
We focused our analysis of neuroblastoma RLGS
patterns on chromosome 1 fragments that exhibited absence
or reduced intensity in tumor patterns compared to control
peripheral blood DNA from the same patients. We had
previously ascertained that 280 DNA fragments in our
standard genomic RLGS patterns were derived from
chromosome 1 [20]. The standard patterns are obtained
using Not I and EcoRV as the initial cutters before the first -
dimension separation and Hin fI as the enzyme cutter for in
situ digestion before the second-dimension separation. A
fragment designated Ch1-113 frequently occurred at
decreased intensity in tumors relative to controls (Figure 1 ).
This fragment was predicted from VGS analysis to be
derived from the p73 gene and its identity was further verified
by cloning.
To obtain sufficient amounts of DNA of chromosome 1
fragments of interest for their cloning, as in the case of
fragment Ch1-113, we constructed a chromosome 1 Not I–
EcoRV fragment library. For the preparation of the library,
chromosome 1 DNA was obtained as described in Materials
and Methods. DNA from the library was used for preparative
RLGS gels of chromosome 1 fragments. Fragment Ch1-
113 was localized in chromosome 1 library RLGS patterns,
leading to its extraction and cloning. We first cloned the
Ch1-113 406-bp Not I–Hin fI fragment directly from RLGS
gels, as described in Materials and Methods. Subsequently,
we used the cloned 406-bp fragment as a probe to screen
the chromosome 1 Not I–EcoRV library. Six Not I–EcoRV-
positive clones were obtained. All six clones had the same
1.7-kb size insert and hybridized with the Ch1-113 406-bp
probe in a Southern blot of cloned DNA. Two of the six
clones were sequenced at the Not I end, and one was
sequenced in its entirety, yielding a 1682-bp insert. The
406-bp sequence occurred in its entirety in the 1682-bp
fragment, beginning at the Not I end. DNA from the fully
sequenced clone was used to spike a whole genomic DNA
preparation before RLGS analysis. The ‘‘spiked’’ RLGS
pattern contained an increased intensity of spot Ch1-113
(Figure 2 ).
The full 1682-bp sequence was found to correspond to
bases 3921–5604 of a subsequently derived sequence for
part of the p73 gene (GenBank AF235000). The 1682-bp
DNA fragment contained 119 bp of the p73 50 nontranslated
region, a 77-bp first exon, and 1486 bp of the first intron.
Figure 1. Close -up sections of RLGS patterns from a neuroblastoma tumor
( right ) and normal DNA from the same subject ( left ). The black arrow points
to reduced intensity of the p73 genomic fragment in the tumor relative to
normal DNA. The white arrow points to an amplified fragment derived from the
N -myc amplicon in the tumor [ 17 ].
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Approximately 1 kb of the 1682-bp fragment, beginning at
the Not I site, was GC rich and contained 90 CpG pairs,
consistent with a CpG island. A TATA-box–like element
occurred 70 bp upstream of the transcribed sequence in p73
mRNA. A MetInd and MatInspector search [24] uncovered
numerous putative binding sites for known transcription
factors in the 1682-bp sequence. Interestingly, two N-myc
binding consensus sequence sites occurred inside the first
intron, at 723 and 1158 bp from the transcription initiation site
(at bases 4095 and 4438 of AF235000).
p73 Deletion and N-myc Amplification in Neuroblastoma
Tumors and Cell Lines
A total of 34 neuroblastoma tumors and control DNAs
were analyzed by RLGS for p73 genomic loss. N-myc
amplification in these tumors was previously analyzed by
Southern blotting. As a control for variation in p73 spot
intensity in RLGS patterns that may be due to polymorphism
at the cut sites, particularly for cell lines that did not have
normal DNA for comparison, we analyzed the p73 spot
intensity in 126 normal RLGS patterns (67 of these DNA
samples were peripheral blood cells from normal individu-
als; 47 were from various normal adult tissues including
brain, breast, muscle, lung, stomach, pancreas, and colon;
and 12 samples were from various fetal tissues including
adrenal ). All RLGS patterns from normal tissues exhibited a
p73 spot intensity that corresponded to two copies in the
genome based on our prior quantitative analysis of spot
intensities in RLGS patterns [25]. These results indicate
lack of polymorphism at the cut sites for the p73 fragment
visualized by RLGS and further point to lack of significant
methylation at the Not I cut site in normal tissues. Sufficient
DNA was available for 17 tumors to also allow Southern blot
analysis of p73 genomic status. In the case of tumors for
which both RLGS analysis and Southern blot analysis were
available, there was a good agreement between p73
fragment intensity in RLGS patterns and p73 band intensity
in Southern blots. Twelve neuroblastoma cell lines were
also analyzed by RLGS and Southern blotting. Eleven
tumors (32.4%) and seven cell lines (58.3%) showed
evidence of deletion in our combined RLGS and Southern
blot analysis (Table 1; Figure 3 ). No tumor or cell line
demonstrated complete loss of both genomic copies of p73.
Seven tumors (20.6%) and seven cell lines (58.3%)
showed N-myc amplification. p73 deletion and N-myc
amplification frequently occurred in the same tumors as 5
of 7 tumors and 4 of 7 cell lines with N-myc amplification
had p73 deletion, while 5 of 11 tumors and 4 of 6 cell lines
with p73 deletion had N-myc amplification. The correlation
between N-myc amplification and p73 deletion in tumors
was statistically significant (P=.0004, 1- tailed Fisher’s
exact test). The correlation remained statistically significant
when cell lines were also included in the statistical analysis.
Both N-myc amplification and p73 deletion in neuroblas-
toma tumors occurred preferentially in advanced stage
tumors (Table 1).
Table 1. p73 and N-myc Genomic Status and Expression in Neuroblastoma
Tumors and Cell Lines.
Tumor
Stage
p73
Deletion
N -myc
Amplification
p73
Expression
N -myc
Expression
Tumors
NBT 1 II No No " #
NBT 2 I No No # "
NBT 3 I No No # "
NBT 4 III No No " No change
NBT 5 IV Yes Yes # "
NBT 6 III No No # "
NBT 7 II No No No change No change
NBT 8 I No No # "
NBT 9 II No No # "
NBT 10 II No No # No change
NBT 11 I No No No change "
NBT 12 IV Yes Yes # "
NBT 13 I No No # No change
NBT 14 IV No No No change No change
NBT 15 IV No No # #
NBT 16 III Yes Yes # "
NBT 17 II No No # "
NBT 18 II No Yes # "
NBT 19 IV Yes Yes # "
NBT 20 IV No No
NBT 21 III Yes No
NBT 22 II No No
NBT 23 II No No
NBT 24 IIb Yes No
NBT 25 IV No No
NBT 26 III Yes No
NBT 27 IVs No No
NBT 28 III No No
NBT 29 IV Yes Yes
NBT 30 III No no
NBT 31 IV Yes yes
NBT 32 IIb No No
NBT 33 IIa Yes No
NBT 34 III Yes yes
Cell lines
STA-NB 3 Yes Yes " "
STA-NB 8 No Yes # "
STA-NB 9 Yes Yes # "
STA-NB 11 Yes Yes
IMR 32 Yes Yes # "
LAN 1 Yes No
KCNR No Yes # "
NGP127 No Yes # "
SHEP No No No change No change
SKNAS Yes No # No change
SKNSH No No No change No change
SY5Y No No No change No change
Figure 2. Close -up sections of RLGS patterns from normal whole genomic
DNA ( left ) and from the same DNA after spiking with cloned p73 genomic
DNA ( right ), demonstrating increased intensity of the p73 genomic fragment.
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Relationship Between Expression of p73 and of N-myc
We relied on semiquantitative RT-PCR to study the
expression of p73 and N-myc in 19 tumors, 4 of which
contained p73 deletion. p73 and N-myc expression was
also investigated in 10 cell lines. The results are summar-
ized in Table 1. RNA from fetal adrenal and brain was used
as a reference for judging the intensity of RT-PCR–derived
N-myc and p73 products. Double primers for N-myc and
p73 were used in the same PCR reactions for each sample
to better allow comparison of the relative abundance of N-
myc and p73 (Figure 4 ). Additionally, PCR analysis of p73
and of N-myc was undertaken using internal primers for
ubiquitin as control. Analysis of normal fetal adrenal and
brain tissue, used as controls, yielded a p73 ratio of approx-
imately 3 to 1. A majority of neuroblastomas analyzed (15 of
19 tumors), including the 4 tumors with p73 deletion, showed
decreased expression of p73. Likewise, 7 of 10 cell lines
including four cell lines analyzed that had p73 deletion,
showed decreased expression of p73. There was a statisti-
cally significant inverse correlation between p73 and N-myc
levels as detected by RT-PCR (P=.03, 1- tailed Fisher’s
exact test ). Increased expression of N-myc was observed in
11 of 19 tumors, only 4 of which had N-myc gene am-
plification. Likewise, increased expression of N-myc was
observed in 6 of 10 cell lines, all 6 of which had N-myc gene
amplification. In most tumors and cell lines, there was an
obvious inverse correlation between p73 and N-myc RNA
levels (Figure 4 ). One noticeable exception was cell line
STA-NB3, in which both N-myc and p73 were highly
expressed. In one tumor (NBT 24) and one cell line
(SKNAS) reduced p73 expression was associated with p73
deletion in the absence of N-myc overexpression. The
decreased p73 expression in the other tumors and cell lines
was associated with N-myc overexpression with or without
p73 deletion.
Reduced p73 Expression in Neuroblastoma Cell Lines
Following N-myc Transfection
Two neuroblastoma cell lines, SH-EP1 [26] and SK-
N-AS [27], were stably transfected with the N-myc gene.
These cell lines were chosen as they are not N-myc
amplified. One cell line (SK-N-AS) contained a p73
deletion, while SH-EP1 contained two p73 gene copies.
p73 and N-myc expression in the N-myc transfected cell
lines was examined by semiquantitative RT-PCR. After
N-myc transfection, both cell lines contained increased
amount of N-myc mRNA and protein (Figure 5A ). p73,
which was detectable at low level in untransfected SK-
N-AS, becomes undetectable following N-myc transfection,
whereas in SH-EP1 cells, p73 levels were substantially
Figure 4. RT-PCR analysis of p73 and N -myc expression in neuroblastoma
tumors and cell lines. Ubiquitin RT -PCR products were used as control. A
fetal adrenal and a fetal brain are included for reference, and the band intensity
of their RT -PCR products for p73, N -myc, and ubiquitin were used as
controls.
Figure 5. (A ) N -Myc expression by Western analysis in SH-EP1 and
SK -N -AS transfectants. The KCNR neuroblastoma cell line with amplified
N -myc was used as a positive control. Equivalent protein loading is confirmed
by GAPDH detection. (B ) Reduced intensity of p73 RT -PCR products in
SK -N -AS and SH -EP1 transfectants expressing N -Myc.
Figure 3. Southern blot analysis of p73 in tumors and cell lines. The filters
were also hybridized with a probe for a gene (GAC1 ) also located on
chromosome 1. The adjusted ratio of intensity of the p73 band relative to the
GAC1 is indicated. The designation NBT refers to tumors. Other designations
refer to cell lines and four normal DNA samples.
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reduced following transfection but remained detectable
(Figure 5B ).
Discussion
The identification of p73 as a novel gene with significant
homology to p53 has evoked the possibility that loss of p73
function may play a role in neuroblastoma and other
cancers that exhibit 1p36 deletion. Evidence that p73
is a candidate tumor-suppressor gene in neuroblastoma
included demonstration that transfection of the p73 gene
into a neuroblastoma cell line that lacks detectable p73
protein resulted in growth suppression and induced neuro-
nal differentiation. [1,14] However, there has been a
paucity of evidence for mutation based inactivation of p73
in neuroblastoma [5,6,28] and a lack of homozygously
inactivated p73 in neuroblastoma tumors with a single copy
N-myc gene [13,29,30]. Nevertheless, a number of studies
have shown reduced expression of p73 in neuroblastoma
[5,6,11,29]. In one study of 28 neuroblastoma tumors, p73
expression levels were found to vary widely among tumors
[6]. Given the potential tumor suppressor role of p73 in
neuroblastoma and the demonstrated role of the N-myc
oncogene in neuroblastoma carcinogenesis, it was of
interest to determine the genomic and expression status
of both genes in neuroblastoma tumors and cell lines. Our
prior quantitation studies of fragment intensities in RLGS
patterns have demonstrated a high measure of sensitivity
of fragment intensity to gene dosage changes [25].
Approximately a third of neuroblastomas in our series,
exhibited deletion of p73 as could be ascertained by
analysis of the intensity of the p73 genomic fragment in
RLGS patterns and by Southern blot analysis. This
frequency is comparable to the frequency of 1p deletions
as determined by Southern analysis reported by others
[31]. None of the tumors exhibited a complete absence of
the p73 genomic fragment in RLGS patterns. Likewise, p73
remained detectable in Southern blots of tumors. Whether
this is related to lack of homozygous deletions or to
contaminating normal tissue could not be determined. It
should be pointed out, however, that neuroblastoma cell
lines also did not exhibit a complete absence of p73
genomic DNA by RLGS and Southern analysis. In our
study, some tumors exhibited reduced expression of p73 in
the absence of an obvious deletion, leading us to determine
the relationship between p73 expression and N-myc
status.
The reduced expression of p73 correlated with over-
expression of N-myc. This inverse correlation was observed
in both tumors and cell lines, a majority of which exhibited
high expression of N-myc and decreased expression of p73.
High expression of N-myc was not limited to tumors and cell
lines with N-myc gene amplification. Other groups have
previously reported high- level expression of N-myc in some
neuroblastomas without N-myc gene amplification [32,33].
Our data suggested that p73 levels may correlate with
N-myc expression rather than N-myc amplification status. It
was, therefore, of interest to demonstrate the effect of
manipulating N-myc levels on p73 expression. Transfection
of N-myc into two neuroblastoma cell lines resulted in a
readily detectable decrease in p73 RNA levels, providing in
vitro evidence that N-myc downregulates p73 expression.
Our data suggest that as part of its normal function, the
N-myc gene may inhibit p73 expression, thus preventing
p73 - induced growth suppression. This inverse relationship
between N-myc and p73 appears to be maintained in some
neuroblastoma tumors in the absence of either N-myc
amplification or p73 deletion. Expression of either gene may
remain subject to regulatory control in tumors that do not
contain p73 or N-myc genomic alterations. However, N-myc
genomic amplification, with or without p73 deletion results in
N-myc overexpression and downregulated levels of p73 that
are characteristic of aggressive tumors.
The initial studies of p73 suggested that it may be a
candidate for the imprinted tumor-suppressor gene at 1p36,
based on its frequent deletion and monoallelic expression
[1]. Allele -specific methylation is a common feature of
imprinted genes [34]. In addition, tissue-specific imprinting
correlates with differential allele-specific DNA methylation
[35]. In our study, the use of the methylation-sensitive
enzyme Not I for both RLGS analysis and Southern analysis
allows assessment of methylation at the Not I site. There was
no evidence in either tumors or normal DNA of any
methylation at the Not I cut site, which is located in a part
of the p73 promoter, close to exon 1. Thus, it is likely that any
methylation that affects allele specific expression of the p73
gene is located elsewhere in the gene.
It remains to be determined whether p73, through its
inactivation, plays a role in neuroblastoma development,
independent of N-myc overexpression. Several studies to
date have failed to detect p73 point mutations more than
occasionally [5,36,37]. One cell line (STA-NB3) in our study
contained an amplified and overexpressed N-myc gene, yet
expressed p73 at a high level. We amplified a 1.1-kb p73
genomic DNA fragment from this cell line and sequenced
three clones containing p73 from this tumor. No sequence
changes were detectable. The high- level expression of p73
in a small number of neuroblastoma tumors and cell lines
may be related to activation of the p73 silent allele, as has
been recently reported to occur in lung cancer [38].
It should be noted that in a recent study [39], the c-myc
gene was found to upregulate p73 expression, while in our
study a downregulation by N-myc was observed. There-
fore, there is a need to reconcile these observations given
the overlap among c-myc and N-myc target genes. These
opposite findings may relate to cell type and differentiation
state. Pertinent to our observations in neuroblastoma are
prior reports that are concordant with our findings. It is well
known that retinoic acid induces neuronal differentiation of
neuroblastoma cells. In one study, treatment of neuro-
blastoma cells with retinoic acid was found to induce p73
[14] and in prior studies, treatment with retinoic acid was
found to decrease N-myc levels [40]. These findings do
indicate a negative correlation between N-myc levels and
p73 in neuroblastoma, which is consistent with our
findings.
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The N-myc gene is known to affect a variety of signaling
pathways [41,42]. An inhibitory effect of N-myc on the
expression of certain genes has previously been reported.
Overexpression of the N-myc gene in a rat neuroblastoma
cell line following gene transfer resulted in reduced
expression of class I histocompatibility antigens [43]. Over-
expression of transfected N-myc in the human SKNSH
neuroblastoma cell line resulted in reduced expression of
beta 1 integrin [44]. Thus, it appears that the ability of the
N-myc gene to induce neuroblastoma formation, through its
overexpression, is related to its ability to positively, as well
as negatively, control the expression of a large number of
target genes that play a role in neuroblast proliferation and
differentiation.
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